EDAP TMS S.A. (FOCL) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. EDAP TMS S.A. (rebranding to FocalTherics) is a medical device company focused on High Intensity Focused Ultrasound (HIFU) technology. Effective January 1, 2026, the Company transitioned from a Foreign Private Issuer to a U.S. domestic issuer and qualifies as a "smaller reporting company."
On May 28, 2026, the Board approved a strategic plan to exit its Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments to focus exclusively on its robotic focal therapy business. These segments are now reported as discontinued operations.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues (Continuing) | $24,796 |
| Gross Profit | $13,300 |
| Gross Margin | 53.6% |
| Operating Loss | $(16,057) |
| Net Loss (Continuing) | $(24,007) |
| Net Loss (Consolidated) | $(23,570) |
| Cash and Cash Equivalents | $21,542 |
| Long-Term Debt | $37,197 |
| Operating Cash Flow | $(6,663) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues from continuing operations increased 54.9% to $24.8 million (vs. $16.0 million in 2025), driven by an 89% increase in medical device sales (24 Focal One units sold) and a 34.1% increase in treatment-driven revenue.
- Margin Expansion: Gross margin improved to 53.6% from 50.1% in the prior year, attributed to cost reductions and favorable fixed cost absorption.
- Expense Increase: Operating expenses rose 37.3% to $29.4 million. Selling and marketing expenses increased to $13.8 million, and General and Administrative (G&A) expenses rose 52.4% primarily due to fees associated with the transition to domestic filer status.
- Financial Expenses: Net financial expense surged to $8.0 million (from $81 thousand) due to a $6.8 million non-cash fair value adjustment on warrants issued to the European Investment Bank (EIB).
- Discontinued Operations: The ESWL and Distribution segments generated a net profit of $437 thousand for the six months ended June 30, 2026, compared to $285 thousand in the prior year.
Guidance, Outlook, and Risks
- Strategic Realignment: The Company is executing a plan to sell the ESWL and Distribution businesses within one year to concentrate resources on the HIFU platform.
- Liquidity: As of June 30, 2026, cash stood at $21.5 million. Management believes this, combined with a subsequent equity offering, supports operations for at least 12 months.
- Subsequent Event: On August 14, 2026, the Company completed an underwritten public offering of 8,425,000 ADSs at $4.75 per share, raising net proceeds of approximately $37.1 million.
- Risks: Key risks include the uncertainty of the disposal process for discontinued segments, potential revenue disruption, reliance on the success of HIFU technology, and significant volatility in financial results due to warrant liability fair value adjustments.
Investor Verification Checklist
- Verify the timeline and terms of the planned sale of ESWL and Distribution segments.
- Monitor the impact of the $37.1 million equity raise on cash runway and dilution.
- Assess the sustainability of gross margin improvements as production volumes scale.
- Review the valuation methodology and volatility assumptions for the EIB warrant liabilities, which significantly impact reported net loss.
- Track the adoption rate of the Focal One HIFU system in the U.S. market, which drove the majority of recent revenue growth.